Characteristics and Treatment Sequences of Patients with KRAS G12C, Other KRAS and KRAS-Wild-Type Advanced or Metastatic (AM) Non-Small Cell Lung Cancer (NSCLC) in the French ESME Cohort

被引：0
|
作者：
Girard, Nicolas [1 ]
Perol, Maurice [2 ]
Debieuvre, Didier [3 ]
Lemonnier, Lydie [4 ]
Veillard, Charlotte [5 ]
Caillon, Megane [5 ]
Tzala, Lia [6 ]
Desamericq, Gaelle [7 ]
Audigier-Valette, Clarisse [8 ]
机构：
[1] Inst Curie, Pneumol Thorax Inst, Paris, France
[2] Ctr Leon Berard, Dept Med Oncol, Lyon, France
[3] Grp Hosp Mulhouse Sud Alsace, Dept Pneumol, Mulhouse, France
[4] UNICANCER, Hlth Data & Partnership Dept, Paris, France
[5] Amgen SAS, Boulogne, France
[6] Amgen Ltd, Uxbridge, Middx, England
[7] Amgen SAS, Courbevoie, France
[8] Ctr Hosp St Musse, Dept Pneumol, Toulon, France
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2024年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
787
引用
收藏
页码：342 / 342
页数：1
相关论文
共 50 条
  • [41] CodeBreaK 200: A Phase 3 Multicenter Study of Sotorasib, a KRAS(G12C) Inhibitor, versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring KRAS p.G12C Mutation
    Reck, M.
    Spira, A.
    Besse, B.
    Wolf, J.
    Skoulidis, F.
    Borghaei, H.
    Goto, K.
    Park, K.
    Griesinger, F.
    Font, E. F.
    Boyer, M.
    Barrios, C. H.
    Goss, G.
    Yang, H.
    Obiozor, C.
    Ramalingam, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S29 - S29
  • [42] Phase I A Study to Evaluate GDC-6036 Monotherapy in Patients with Non-small Cell Lung Cancer (NSCLC) with KRAS G12C Mutation
    Sacher, A.
    Patel, M. R.
    Miller, W. H., Jr.
    Desai, J.
    Garralda, E.
    Bowyer, S.
    Kim, T. W.
    De Miguel, M.
    Falcon, A.
    Krebs, M. G.
    Lee, J.
    Cheng, M.
    Han, S. -W.
    Shacham-Shmueli, E.
    Forster, M.
    Jerusalem, G.
    Massarelli, E.
    Paz-Ares Rodriguez, L.
    Prenen, H.
    Walpole, I.
    Arbour, K.
    Choi, Y.
    Dharia, N. V.
    Lin, M.
    Mandlekar, S.
    Joo, S. Royer
    Shi, Z.
    Schutzman, J.
    LoRusso, P.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S8 - S9
  • [43] Non-genetic determinants driving sub-clonal resistance to KRAS G12C combination therapies in KRAS mutant non-small cell lung cancer
    Li, Chendi
    Graser, Christopher J.
    Qin, Qian
    Syed, Usman M.
    Karakyriakou, Barbara
    Clark, Sarah E.
    Saiki, Anne Y.
    Hughes, Paul E.
    Ott, Christopher
    Pinello, Luca
    Michor, Franziska
    Hata, Aaron N.
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [44] Prevalence of KRAS p.G12C mutation in patients with metastatic non-small cell lung cancer in Argentina
    Mendoza Bertelli, Andrea
    Otero Pizarro, Maria Mercedes
    Fernandez, Maria Paz
    Dibarbora, Delfina
    Florencia Cantarella, Maria
    Damian Mahmoud, Yamil
    Girotti, Romina
    Guttlein, Leandro
    Chico, Isagani
    Brandalise, Patricia
    Dutra, Carolina
    Salanova, Ruben
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [45] Targeting KRAS-Mutant Non-Small-Cell Lung Cancer: One Mutation at a Time, With a Focus on KRAS G12C Mutations
    Burns, Timothy F.
    Borghaei, Hossein
    Ramalingam, Suresh S.
    Mok, Tony S.
    Peters, Solange
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (35) : 4208 - 4218
  • [46] Efficacy of JS']JSI-1187 or VIC-1911 in combination with KRAS G12C inhibitors for the treatment of KRAS G12C-mutated non-small cell lung cancer and colorectal cancer
    Zhang, Lei
    Li, Ao
    Jian, Shanzhong
    Du, Chengyi
    Zhu, Wan
    Tao, Yue
    Wang, Meiwei
    Xu, Wen
    Hao, Wenshan
    Paradiso, Linda
    Myers, Thomas
    Koya, Keizo
    Zhang, Jintao
    CANCER RESEARCH, 2023, 83 (07)
  • [47] Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C-Mutant Non-Small Cell Lung Cancer
    Adachi, Yuta
    Ito, Kentaro
    Hayashi, Yuko
    Kimura, Ryo
    Tan, Tuan Zea
    Yamaguchi, Rui
    Ebi, Hiromichi
    CLINICAL CANCER RESEARCH, 2020, 26 (22) : 5962 - 5973
  • [48] Assessing the significance of KRAS G12C mutation: Clinicopathologic features, treatments, and survival outcomes in a real-world KRAS mutant non-small cell lung cancer cohort.
    Cui, Wanyuan
    Franchini, Fanny
    Alexander, Marliese
    Officer, Ann
    Wong, Hui Li
    IJzerman, Maarten J.
    Desai, Jayesh
    Solomon, Benjamin J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [49] 31507: Phase II study of docetaxel and trametinib in patients with G12C or non-G12C KRAS mutation positive (+) recurrent non-small cell lung cancer (NSCLC).
    Gadgeel, Shirish M.
    Miao, Jieling
    Riess, Jonathan W.
    Mack, Philip C.
    Gerstner, Gregory James
    Burns, Timothy F.
    Taj, Asma
    Akerley, Wallace L.
    Dragnev, Konstantin H.
    Moon, James
    Gandara, David R.
    Kelly, Karen
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [50] Suppression of mutant Kirsten-RAS (KRAS G12C) non-small cell lung cancer (NSCLC) resistance to KRAS G12C inhibitors by dual inhibition of hepatocyte growth factor receptor (MET) and V-ATPase
    Rosell, R.
    Gomez-Vazquez, J. L.
    Lewintre, E. Jantus
    Ito, M.
    Cao, P.
    Cai, X.
    Xing, B.
    Farinas, S. Calabuig
    Cardona, A. F.
    Rodriguez, J. K.
    Jordan, M. Marco
    Valdunciel, C. Pedraz
    Molina-Vila, M. A.
    Codony-Servat, J.
    Dantes, Z.
    Aguilar, A.
    Sullivan, I. G.
    Horno, I. Moya
    Cirera, L.
    Gonzalez-Cao, M.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S149 - S149
12345